Stephen E. Butts, Chief Executive Officer
Steve is a co-founder and the CEO of Arrivo BioVentures, LLC, a drug development company. He has over 25 years of experience in the pharma/biotech industry with and a track record of successful fund raising, product licensing and M&A with start-up companies. Most recently, Steve was CEO of Velo Bio, a start-up company with a drug in development for severe preeclampsia. Velo was sold to AMAG Pharmaceuticals in 2018. Prior to Velo, he was co-founder, President and COO of Aerial BioPharma LLC, a drug development company that sold its lead drug for narcolepsy to Jazz Pharmaceuticals in 2014. Prior to Aerial, Steve was co-founder and Executive Vice President of Neuronex Inc, acquired by Acorda Therapeutics in December 2012. Additionally, he was an original member of the executive team at Addrenex Pharmaceuticals and played a key role in the company’s sale to Shionogi Pharma in 2009. He has also served as Vice President of Sales & Marketing at BioBehavioral Diagnostics Company, as well as assignments at Eli Lilly and Company and Braintree Laboratories.
Steve is currently a member of the Board of Directors and on the Audit Committee of Areteia Therapeutics. He is also on the Board of Directors of Knopp Biosciences and Otologic Pharmaceutics.
Steve holds a BS degree in Business Administration from the University of North Carolina at Chapel Hill and an MBA from the Kenan-Flagler School of Business at the University of North Carolina at Chapel Hill.
